Immediate Action Required – Epinephrine Auto Injector Devices

Date: June 17, 2020 To: Health Plan of San Joaquin (HPSJ) Pharmacies and Providers & Practices From: HPSJ Pharmacy Department Subject: Immediate Action Required – Epinephrine Auto Injector Devices Business: Medi-Cal We are sending this alert because your patient(s) may have filled a prescription for Epinephrine Auto-Injector Device since December 20, 2018. FDA is alerting […]

Read more

Clinical Guideline: Reproductive Health in Rheumatic and Musculoskeletal Diseases

The American College of Rheumatology recently published the organization’s first guideline on how to manage reproductive health issues in patients with rheumatic and musculoskeletal diseases (RMDs). Patients with RMDs face unique challenges as pregnancy may be associated with serious maternal or adverse fetal outcomes; furthermore, it is difficult to avoid use of medications in patients […]

Read more

NP Thyroid recall provider alert

Date: May 28, 2020 To: Health Plan of San Joaquin (HPSJ) Pharmacies and Providers From: HPSJ Pharmacy Department Subject: NP Thyroid Recall Business: Medi-Cal We are sending this alert because your patients may have filled a prescription for NP Thyroid 30mg, 60mg or 90mg within the last six months (180 days). With FDA knowledge, Acella […]

Read more

Formulary Update Effective 8/3/2020

Date: May 22, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: HPSJ Pharmacy and Therapeutics Committee Subject: Formulary Update Business: Medi-Cal Effective August 3, 2020, the Pharmacy and Therapeutics Committee has approved the following changes. Additions to the Formulary: 1. Dulaglutide (Trulicity) 0.75 mg/0.5 mL, 1.5mg/0.5ml pen: PA required. Reserved [...]

Read more

Drug Safety Communication: Withdrawal of All Ranitidine Products

Drug Safety Communication: Withdrawal of All Ranitidine Products Ranitidine is a histamine-2 blocker commonly used as an over-the-counter (OTC) medication to relieve and prevent heartburn. Prescription-strength ranitidine is also used to treat and prevent more serious ulcers in the stomach and intestines. On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested a […]

Read more

Improving Quality of Care: Update of Risks Associated with Use of Fluoroquinolones

Learning Objectives: Describe the recent U.S. Food and Drug Administration (FDA) drug safety communications for fluoroquinolones. Identify potential adverse effects associated with use of fluoroquinolones. Summarize best practices for responsible prescribing of fluoroquinolones. Key Points: Fluoroquinolones are broad-spectrum antibiotics that are FDA-approved to treat various bacterial infections, including infections caused by gram-negative bacilli. Over the […]

Read more

Mitigating health impacts: Secondary Stress due to the COVID-19 pandemic

Date: April 13, 2018 To: HPSJ Providers (HPSJ) Providers, Practices, and Facilities From: HPSJ Provider Services Department Subject: Mitigating health impacts: Secondary Stress due to the COVID-19 pandemic) Business: Medi-Cal “First and foremost, HPSJ appreciates you - providers, practitioners, and facilities - for your tremendous commitment to take care of patients with the COVID 19 [...]

Read more

Drug Safety Communication: Mental Health Side Effects from Montelukast

Montelukast is a leukotriene receptor antagonist approved for asthma and allergies. On March 4, 2020, the U.S. Food and Drug Administration (FDA) announced it is strengthening existing warnings about serious behavior and mood-related changes with montelukast. While the prescribing information for montelukast already includes warnings about mental health side effects, including suicidal thoughts or actions, [...]

Read more

ALL Ranitidine Products Recall – Immediate Action Needed

Date: April 3, 2020 To: Health Plan of San Joaquin (HPSJ) Pharmacies and Providers & Practices From: HPSJ Pharmacy Department Subject: ALL Ranitidine Products Recall – Immediate Action Needed Business: Medi-Cal We are sending this alert because your patient(s) may have filled a prescription for Ranitidine within the last six months (180 days). Issue: The […]

Read more

Pharmacy Updates – During COVID-19 (Coronavirus)

Date: March 31, 2018 To: HPSJ Providers, Practices (PCPs & Specialists), Hospitals and Ancillary Facilities From: HPSJ Provider Services Department Subject: Pharmacy Updates – During COVID-19 (Coronavirus) Business: Medi-Cal PHARMACY UPDATES – Health Plan of San Joaquin has notified our Pharmacy Network and our PBM (MC-Rx Powered by ProCare Rx) to authorize early refills for […]

Read more

1 2 3 7
top
X